For our investors

Basilea reported strong revenue growth and significant pipeline progress for full-year 2018

Read more

Our future growth and value generation is based on increasing revenues from our two marketed anti-infectives and positive data from our innovative pipeline

Investing in Basilea

  • Growing revenues: we continue to grow revenues from Cresemba and Zevtera, including launches in further markets
  • Building global brands: we strengthen and fully exploit the commercial potential from our marketed products. Our commercialization partnerships cover more than 100 countries
  • Solid cash position: allows us to explore opportunities to selectively expand our clinical oncology portfolio and pre-clinical pipeline through in-licensing and internal development
  • Growth potential: we are focused on advancing and expanding our R&D portfolio to create sustainable shareholder value

Current investor presentation

Events and presentations

Aug 20. 2019
2019 Half-Year Results and publication of Half-Year Report 2019

Conference call: 4:00 p.m. CEST

Webcast

For questions, please additionally dial-in via phone.

+41 (0) 58 310 5000     (Europe and RoW)
+1 (1) 866 291 4166       (USA)
+44 (0) 207 107 0613    (U.K.)

Replay:
The webcast, along with presentation will be available online shortly after the event and accessible for three months.

Jun 25. 2019
Basel, Switzerland
UBS European Healthcare Bus Tour
Jun 04. 2019
New York, United States
Jefferies Global Healthcare Conference
May 21. 2019
New York, United States
UBS Global Healthcare Conference

Presentation at 2:30 - 3:00 p.m. EDT

Webcast

20190521_Basilea Corporate Presentation_David Veitch

May 09. 2019
Zurich, Switzerland
CITI Healthcare day

 

Archive

Annual General Meeting

Apr 10. 2019, 14:00 CEST
Radisson Blu Hotel in Basel, Switzerland
2019 Annual General Meeting of Shareholders

 

Archive

Analyst coverage

The analysts listed on this page have published reports or commentary on Basilea; there may be other analysts who have published reports or commentary that are not referenced here.  Please note that any opinions, estimates or forecasts regarding Basilea's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Basilea or its management.  Basilea does not by its reference on this website imply any endorsement of or concurrence with such information, conclusions or recommendations.

FIRM ANALYST
Baader Helvea Bank Bruno Bulic
Bryan Garnier & Co. Victor Floc’h
Cantor Fitzgerald (U.K.) Brian White
Cantor Fitzgerald (U.S.) Louise Chen
Edison Susie Jana
goetzpartners securities Limited Brigitte de Lima
Kepler Cheuvreux Arsene Guekam
LifeSci Capital David Sherman
Mirabaud Securities Limited Olav Zilian
NIBC Bank N.V. Dylan van Haaften
Research Partners AG Paul Verbraeken
valuationLAB AG Bob Pooler

 

Share information

Corporate Governance

Articles of Association

Articles of Association

Statuten

Archive

Organisational Regulation

Organisational Regulation

Archive

Long-term incentive plan

Basilea has implemented a long-term incentive plan in the form of stock options, which vest after 3 and 4 years. The purpose of the Basilea stock option program is to provide Management Committee members and certain key employees with an opportunity to obtain stock options (or alternatively, stock appreciation rights), thus providing an incentive for participants to contribute to the mid and long-term success of the Company. The program is therefore aligned with shareholders’ interest to enhance shareholder value and also increases the ability of the Company to attract and retain individuals with exceptional skills. The plan has been amended to allow for gross and net settlement of stock options, which will be applied by the Company to ensure that the maximum potential dilution related to all granted options will stay below 10% of the share capital on a fully diluted basis.

Significant shareholders

SIX Website